# Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants

> **NCT06889740** · NA · COMPLETED · sponsor: **EffePharm LTD** · enrollment: 80 (actual)

## Conditions studied

- Healthy Aging

## Interventions

- **OTHER:** NMNH
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06889740
- **Lead sponsor:** EffePharm LTD
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-08
- **Primary completion:** 2024-12-08
- **Final completion:** 2025-01-25
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889740, "Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06889740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*